HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Tibolone in the treatment of psychosomatic symptoms in menopause.
The purpose of this study was to investigate the value of tibolone in the treatment of psychosomatic symptoms in menopause . Forty-two menopausal women ( aged 46 - 63 , mean 53.9 ) with nightly perspiration , vasomotor flushes , disturbance of libido , dyspnea and other psychosomatic symptoms  were assigned to one of two treatment groups for three months : 1st group ) 21 users of tibolone ; 2nd group ) 21 users of placebo . At the end of the trial disturbance of libido was observed in 4 ( 19.0 % ) cases tin the 1st group and 11 ( 52.4 % ) cases in the 2nd ( p < 0.05 ) and nightly perspiration was observed in 3 cases ( 14.3 % ) in the 1st group and 9 cases ( 42.9 % ) in the 2nd ( p < 0.05 ) . Although vasomotor flushes were observed in only 3 ( 14.3 % ) cases in the 1st group and 7 cases ( 33.3 % ) in the 2nd group , this difference was not significant ( p > 0.05 ) . There was no significant effect of tibolone or placebo in dyspnea , vertigo and headache . From the results it can be concluded that tibolone can have a beneficial effect on some psychosomatic symptoms in postmenopausal women
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .